Home » Newsletters » BioWorld Science

BioWorld Science

May 7, 2020

View Archived Issues

Polymerase kappa and drug resistance

Sphingolipids accumulate in neurodegeneration

Carbohydrate metabolism implicated in neuropathy

Merck & Co. presents data from RESTORE-IMI 2 phase III study of Recarbrio

TGen and HonorHealth initiate study of atovaquone plus azithromycin in COVID-19

Topline data shows multifactorial activity of AXA-1125 and AXA-1957 in NAFLD

Nimbus Lakshmi patents TYK2 inhibitors

First-in-human data presented for KA-2507

NiKang Therapeutics synthesizes new HIF-2alpha inhibitors

Merck & Co. identifies IDO1 inhibitors

Suven Life Sciences describes new muscarinic M1 receptor PAMs

New SERPINA1 modulators presented by Vertex Pharmaceuticals

EOS-100850 shows excellent tolerance and clinical benefit in refractory solid tumors

New mouse model of mild spinal muscular atrophy

Amgen reports topline data from phase III study of Otezla for mild to moderate plaque psoriasis

New phase III study evaluates lenzilumab in hospitalized patients with COVID-19

DongWha Pharm plans phase II evaluation of DW-2008 for COVID-19

HIF-1alpha stabilizer GB-004 well tolerated in multiple-dose phase I study

Lineage Cell Therapeutics updates phase I/IIa results with OpRegen for dry AMD

FDA approves Elyxyb for acute treatment of migraine with or without aura

Enanta reports topline phase II data on EDP-305 in primary biliary cholangitis

FDA approves Tabrecta for metastatic NSCLC with METex14

FDA clears new phase I study of NBTXR-3 activated by radiation therapy for pancreatic cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...